Antibody Vaccines

Antibody Vaccines Global Market Outlook:

• The Global Antibody Vaccines Market: $2.07 billion in 2023 and expected to reach $2.56 billion by 2025F

• Large CROs & CDMOs have been continuously expanding their supply base through acquisitions and collaboration to provide integrated services related to vaccine testing and development

• Rise in the prevalence of several diseases is promoting technological advancements in faster production of vaccines and a large number of international vaccination programs, government and non-government initiatives, and an increase in demand for the combined vaccine is responsible for the boost in the market growth.

Antibody Vaccines Market Overview

The antibody vaccine market showed gradual growth and was valued at $2.07 billion in 2023 and is expected to reach $2.56 billion by 2025, growing at a CAGR of 11 percent. Monoclonal antibodies constitute about 30 percent of the total biopharmaceutical drug sales.

Industry Growth Drivers

• The growth in the global vaccines market is mainly attributed to the strong pipeline for vaccines, increasing government focus on immunization programs, and technological progress in vaccines administration

• Collaborations between global organizations and governments of various nations to promote the supply of essential drugs and medical supplies will fuel market growth

Industry Growth Constraints

• High cost associated with antibody vaccine development and longer timelines for vaccine manufacturing hinders the growth of this market to some extent

• However, factors such as herd immunity, and uncertainty over the efficacy of vaccines and drugs are expected to hinder the market growth

Antibody Vaccines Regional Analysis

• Currently, North America is still the leader in vaccine development outsourcing as most experienced scientists and CROs are based in the US and Canada

• Pharmaceutical companies in North America have also been outsourcing the vaccine development and testing to a significant degree since the late 1980s. Europe had a less well developed infrastructure and less experience, but is rapidly advancing

Porter's Analysis on Antibody Vaccines

Supplier Power

• Supplier power is medium as most of the buyers enter into strategic relationships with the preferred suppliers

• Most of the buyers have particular set of suppliers to be considered for the development process. This is based upon the various technologies and
  processes available.

Barriers to New Entrants

• Set up and scale up of mammalian cell cultures require time.

• Buyers prefer to go for strategic relationships in this category. Suppliers currently existing in the market have working relationships with various buyers and the entry of a new entrant would be difficult.

Intensity of Rivalry

• The rivalry faced by the CDMOs is not from the direct competitors, but rather an influx of capacity from the players who were product manufacturers earlier.

• The differences in the established volume, processes, technologies differentiates the various suppliers in the supply space.

• The CDMO space is growing at a rate greater than the increase in demand.

Threat of Substitutes

• Antibodies operate by mimicking the natural defense mechanism of the human body, and is really effective the areas of Cancer and auto immune diseases.

• Unless a new technology/process can find an alternative for the treatment, the threat of substitute is really low.

Buyer Power

• The utilization rates of the supplier facilities are expected to drop going foreword as the suppliers and buyers are expanding at a rate higher than the
  increase in supply.

• Most of the buyers outsource high volumes to a supplier often leading to the allotment of a dedicated space.